ANAB Live signals | Maximize Profits with Getagraph.com

BUY 159456 min ago

@ $22.40

Issued: 13 Feb 2024 @ 09:30

Return: 6.88%

Previous signal: Feb 12 - 09:36

Previous signal: Sell

Return: -3.80 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications...

Stats
Today's Volume	277 971
Average Volume	377 722
Market Cap	654.01M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-1.560 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.90
ATR14	$0.0380 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-22	Mulroy Dennis	Sell	1 500	Common Stock
2024-03-22	Faga Daniel	Sell	145 940	Common Stock
2024-03-25	Faga Daniel	Sell	3 000	Common Stock
2024-03-26	Faga Daniel	Sell	347 441	Common Stock
2024-02-16	Loumeau Eric J	Sell	5 000	Employee Stock Option (right to buy)

INSIDER POWER
36.40
Last 98 transactions
Buy: 2 547 267 \| Sell: 1 265 029

Volume Correlation

Long: -0.10 (neutral)

Short: 0.48 (neutral)

Signal:(48.524) Neutral

AnaptysBio Inc Correlation

10 Most Positive Correlations
OZEM	1
PSTR	0.853
BWIN	0.846
BOTT	0.818

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AnaptysBio Inc Correlation - Currency/Commodity

-0.39
( neutral )

-0.29
( neutral )

0.00
( neutral )

-0.14
( neutral )

0.11
( neutral )

0.42
( neutral )

AnaptysBio Inc Financials

Annual	2023
Revenue:	$17.16M
Gross Profit:	$14.78M (86.15 %)
EPS:	$-6.08

FY	2023
Revenue:	$17.16M
Gross Profit:	$14.78M (86.15 %)
EPS:	$-6.08

FY	2022
Revenue:	$10.29M
Gross Profit:	$7.95M (77.30 %)
EPS:	$-4.57

FY	2021
Revenue:	$63.18M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.11

Financial Reports:

No articles found.

AnaptysBio Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

AnaptysBio Inc

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.